ÂÜÀòÂÒÂ×

Doug Sills is a seasoned professional in corporate development and venture capital, currently serving as a General Partner at Anthem Venture Partners. Sills has held notable positions including Vice President of Corporate Development at both ImmunoVec and Celenex Therapeutics, the latter of which was acquired by Amicus Therapeutics. Prior to these roles, Sills worked as an Associate at Moonshots Capital and gained experience as a Senior Analyst in PBM Operations and Senior IT Project Manager at CVS Health. Sills holds a Bachelor of Science in Finance from Indiana University - Kelley School of Business, awarded between 2008 and 2012.